Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31496742 | 1.00 | PTPRC (0.63) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL8772960 | 0.93 | ALDH1A1 (0.57) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL2608412 | 0.89 | KEAP1 (0.59) | PTPRCTSHRLMNAACHEALDH1A1 | |
| Propionaldehyde SCHEMBL28841522 | 0.88 | PTPRC (0.52) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL9734076 | 0.88 | PTPRC (0.63) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL28841521 | 0.87 | PTPRC (0.55) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL14744311 | 0.86 | PTPRC (0.61) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL28549165 | 0.86 | PTPRC (0.61) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL11214966 | 0.85 | PTPRC (0.59) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL14292542 | 0.85 | PTPRC (0.59) | PTPRCTSHRLMNAACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114507252-B | Novel method for synthesizing arylsilane compound | 广西大学 | 2023-10-27 | — | — | CN | claimed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| CN-118146102-A | Method for synthesizing diaryl amine or triarylamine by using nitroaromatic hydrocarbon as raw material | 广西大学 | 2024-06-07 | — | — | CN | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20070014833-A1 | Treatment of eye disorders with sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
| US-5466871-A | Amination of a nitrobenzene with a hydroxylamine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-11-14 | — | — | US | disclosed |
| EP-0103990-A1 | Process for making diarylamines | UNIROYAL, INC. (US) | 1984-03-28 | — | — | EP | disclosed |
| US-4431841-A | REACTING PRIMARY AROMATIC AMINES AND ALICYCLIC KETONES USING AN ACID PROMOTER AND A PLATINUM CATALYST | UNIROYAL, INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4171425-A | ANIONIC CATALYST, 2-PYRROLIDONE OR E-CAPROLACTAM | CHEVRON RESEARCH COMPANY (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | PTPRC 1071/4885TSHR 3550/4885LMNA 3425/4885 |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | PTPRC 779/4885TSHR 818/4885LMNA 2850/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | PTPRC 1546/4885TSHR 1299/4885LMNA 3321/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | PTPRC 345/4885TSHR 4595/4885LMNA 1377/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | PTPRC 849/4885TSHR 4253/4885LMNA 935/4885 |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | PTPRC 2282/4885TSHR 692/4885LMNA 4645/4885 |
| US-20070014833-A1 | Treatment of eye disorders with sirtuin modulators | SIRT1, SIRT2, SIRT3 | PTPRC 4537/4885TSHR 994/4885LMNA 3964/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PTPRC 231/4885TSHR 2387/4885LMNA 2749/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | PTPRC 1071/4885TSHR 3550/4885LMNA 3425/4885 |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | PTPRC 200/4885TSHR 2226/4885LMNA 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.